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ABSTRACT 
Background and Aims: We tested the hypothesis that an intervention with 
Mediterranean diet (MeDiet) could mitigate the well-known harmful effects of 
abdominal obesity on cardiovascular health. 
Methods and Results: We assessed the relationship between baseline waist-to-height 
ratio (WHtR) and major cardiovascular events during a median follow-up of 4.8 years 
in the PREDIMED randomized primary prevention trial which tested a MeDiet 
against a control diet (advice on a low-fat diet). We also examined whether the 
MeDiet intervention was able to counteract the detrimental cardiovascular effects of 
increased WHtR. The trial included 7447 participants (55-80 years-old, 57% women) 
at high cardiovascular risk but free of CVD at enrollment. 
An increased risk of CVD events (myocardial infarction, stroke, or cardiovascular 
death) was apparent for the highest versus the lowest quartile of WHtR 
(multivariable-adjusted hazard ratio: 1.92 (95% confidence interval: 1.08-3.40, linear 
trend: p=0.023) only in the control diet group, but not in the two groups allocated to 
intervention with MeDiet (p for interaction = 0.047). This interaction suggesting that 
the intervention counterbalanced the detrimental effects of adiposity was also 
significant for BMI (p<0.001) and waist circumference (p=0.043). 
Conclusions: The MeDiet may counteract the harmful effects of increased adiposity 
on the risk of CVD. 
 




Excess body weight is likely to be associated with clinical cardiovascular disease 
(CVD) even at moderate levels of overweight. Sound biological plausibility and 
recent empirical studies support that the adverse consequences of obesity are mainly 
attributable to abdominal fat accumulation. [2,3,4,5].  We assessed the association 
between adiposity indexes and CVD in the PREDIMED study, a randomized nutrition 
intervention trial comparing a Mediterranean diet (MeDiet) supplemented with extra-
virgin olive oil (EVOO) and a MeDiet supplemented with nuts against a control low-
fat diet for the primary prevention of CVD in older subjects at high cardiovascular 
risk [6]. We tested the hypothesis that the MeDiet would counteract or mitigate the 
detrimental effects of abdominal obesity. Although the final results of the 
PREDIMED trial [8] supported that a MeDiet was able to prevent CVD, there is 
scarce information from randomized trials on whether the MeDiet can specifically 




The design, objectives and methods of the PREDIMED trial were previously 
published. [6]. Briefly, PREDIMED was a randomized, multicenter, cardiovascular 
primary prevention trial conducted in Spain (www.predimed.es) from October 2003 
to December 2010 that compared three dietary interventions: two MeDiets, one 
supplemented with EVOO and the other supplemented with mixed nuts, versus a 
control (low-fat) diet.  
The Institutional Review Boards at all study locations approved the protocol. The trial 
was registered at http://www.controlled-trials.com/ISRCTN 35739639.  
Subjects 
By study design all participants were at high cardiovascular risk because of the 
presence of type-2 diabetes or at least three risk factors, but had no CVD at enrolment 
[6]. Of 7,447 recruited participants, 43% were men 55 to 80 years-old and 57% were 
women 60 to 80 years-old.  
The procedures and specific details of the intervention have been previously described 
[7, 8]. Of note, energy restriction was not part of the nutritional intervention. 
Measurements  
Registered nurses previously trained and certified to implement the PREDIMED 
protocol directly measured weight, height and waist circumference (WC) of 
participants, as previously described [6,7,9]. Height (m) and weight (kg) were 
measured with light clothing and no shoes with calibrated scales and a wall-mounted 
stadiometer, respectively; BMI was calculated as the weight in kilograms divided by 
the square of the height in meters; WC was measured midway between the lowest rib 
and the iliac crest using an anthropometric tape; and waist-to-height ratio (WHtR) 
was calculated as WC divided by height, both in centimetres.  
Outcome 
The main outcome was a composite primary end-point including myocardial 
infarction, stroke, or death from cardiovascular causes. Repeated contacts with 
participants and family physicians, a yearly review of medical records, and 
consultation (every 6 months) of the National Death Index provided the basic 
information used by the end-point adjudication committee to classify the events. 
Members of this committee were blinded to study-group assignments and to the 
anthropometric indexes of participants. 
Assessment of confounders 
Medical, socio-demographic, and lifestyle variables were collected in a baseline 
interview. We used the Minnesota validated physical activity questionnaire to assess 
leisure-time physical activity [10,11]. Dietary habits were ascertained through a semi-
quantitative 137-item food frequency questionnaire previously validated in Spain 
[12].  
Statistical analyses 
We used Cox regression models to assess the hazard ratios (HR) and their 95% 
confidence intervals for total CVD events across quartiles of WHtR (quartile 2 and 3 
were merged to simplify the results), BMI (cut-off points: 25 and 30 kg/m
2
) and WC. 
We adjusted for the following potential confounders measured at baseline: age, sex, 
smoking, diabetes, hypertension status, dyslipidemia status, intervention group, 
METs-min/d (adding a quadratic term to account for a non-linear association with 
cardiovascular events),  and family history of early-onset coronary artery disease. We 
evaluated the interaction between baseline indexes of adiposity and the intervention 
using the likelihood ratio test, after merging in a single category the 2 active arms of 
the trial that received the MeDiet intervention. For WHtR we used the 75
th
 percentile 
as cut-off point to dichotomize the WHtR (1 degree of freedom). To better guarantee 
comparisons to other studies, we used sex-specific cut-off points for WC according to 
widely accepted international recommendations (13). We also repeated the analyses 
using the 90
th
 sex-specific percentile of WC as cut-off point, as suggested by our 
dose-response analysis.  For BMI, the commonly accepted cut-off points (those 
established by the WHO) were used. We evaluated the interaction between WC 
(dichotomized at the 90
th
 sex-specific percentile) and the intervention and between 
BMI (2 categories, cut-off=30 kg/m
2
) and the intervention (2 categories) on 
cardiovascular events using the likelihood ratio test (1 degree of freedom). Analyses 
were performed using STATA version 12.1 (StataCorp, College Station, TX, USA). 
 
RESULTS 
We observed 288 incident CVD events during a median follow-up of 4.8 years (the 
time of follow-up was described by the index person-years). Table 1 shows baseline 
characteristics of participants by intervention groups. Dietary variables at the 
beginning and at the end of the trial are presented in table 2. Table 3 shows the 
relationship between WHtR quartiles and the risk of CVD. The HRs showed an 
increased risk in the upper (versus the lowest) quartile, but this direct association was 
only apparent in the control group. A significant linear trend (p= 0.023) was also 
apparent only in the control group. No association was not observed in the 2 groups 
that received MeDiet interventions. 
The interaction between baseline WHtR (dichotomized at the 75th percentile, 
WHtR>=0.67) and the intervention was statistically significant (p=0.047), showing 
that the detrimental effect of a higher baseline WHtR was apparent in the control diet 
group, but not in the groups randomly allocated to MeDiets. 
In table 4 we show the relationship between WC or BMI and CVD. No significant 
association was found for WC using conventional cut-offs points. However, when we 
dichotomized WC at the 90th sex-specific percentile (>=112 cm in females and 
>=115 cm in males), the multiple adjusted HR associated with waist>90th percentile 
was 1.96 (95% CI: 1.15-3.33) in the control group whereas it was only 0.97 (0.59-
1.58) in both intervention groups merged (p for interaction = 0.043). The risk of CVD 
did not significantly change across conventional categories of BMI within any of the 
three groups. The multivariable-adjusted HR for the highest (>30) versus the lowest 
(<25) category of BMI was 1.56 (95% CI: 0.64-3.78) in participants allocated to the 
control group, whereas it was 0.90 (0.54-1.49) in both MeDiet groups merged 
together. The interaction between a high BMI (>30 kg/m
2
) and the intervention 
(Mediet versus control) was highly significant (p for interaction=0.0096).  
 
Figure 1 presents the multivariable-adjusted HRs for the joint cross-classification 
according to both the values of the WHtR (either below the 75
th
 percentile [<0.67] or 
above it [>=0.67]) and the intervention groups (the two active arms receiving 
MeDiets merged together or the control diet group). The reference category was the 
control diet group with WHtR below the 75
th
 percentile.  
 
DISCUSSION 
In this nutritional intervention trial comparing two supplemented MeDiets versus a 
control diet (advice on a low-fat diet) for incident CVD events, we found that the 
MeDiets counteracted the harmful effect of abdominal adiposity regarding the risk of 
CVD events. The MeDiet has been associated with beneficial metabolic effects, 
regardless of abdominal adiposity in previous studies [14]. But, therewith, we 
assessed an important benefit of the MeDiet in persons with abdominal adiposity, the 
acknowledgedly most harmful type of obesity, which is related to higher risk of 
cardiovascular events. The major strength in our study is that we were able to use the 
results of an intervention with a randomized design. 
Given that recent studies have suggested that the WHtR ratio is one of the best 
indexes to predict diabetes or CVD, we used this ratio as an anthropometric index of 
adiposity to assess the relationship of adiposity with cardiovascular events. Because 
this index has the ability to measure more precisely central obesity than other 
anthropometrical measurements such as BMI [2,3,4,5, 15]. However, the apparent 
interaction was also replicated with WC and BMI.  
Obesity, specially abdominal obesity contributes to produce a state of low-grade 
inflammation that increases cardiovascular risk and as a result it could lead to a higher 
risk of cardiovascular events. The biological mechanism underlying the apparent 
interaction that we have found is likely to be explained by the known anti-
inflammatory properties of the MeDiet, specially when it is supplemented with extra-
virgin olive oil as it has been previously reported using circulating inflammatory 
biomarkers [9, 16] 
The main strength and novelty of our research is that the outcomes were ascertained 
after a long-term (median 4.8 years) dietary intervention in a randomized trial. The 
significant interactions between the intervention and adiposity suggests that the 
MeDiet intervention was able to counteract the higher risk of CVD associated with 
increased adiposity, a finding consistent with the main results of the PREDIMED trial 
[8], which provided strong evidence for the MeDiet as a preventive strategy against 
CVD. Previous studies such as the Women’s Health Initiative Dietary Modification 
Trial (WHI-DMT) [17], did not find that an intervention with a low-fat diet could 
prevent cardiovascular clinical events. The WHI-DMT low-fat diet had no significant 
effects on incidence of coronary heart disease (HR=0.97; 95% CI: 0.90-1.06), stroke 
(1.02; 0.90-1.15), or CVD (0.98: 0.92-1.05). We, in contrast, observed a reduction in 
the incidence of CVD in the two active intervention groups of the PREDIMED trial 
and furthermore, this intervention with a relatively fat-rich diet nullified the 
detrimental effects of abdominal adiposity. 
We speculate that a longer follow-up (for example, after 10-year) could allow us to 
observe similar results in the long-term on other end-points (total mortality or cancer) 
that probably will require a longer induction period. 
There were other strengths in our research such as the use of multiple-adjusted models 
to control for confounding. 
On the other hand, we acknowledge some limitations of our study. The elderly 
population at high cardiovascular risk studied in our cohort limits the generalizability 
of our findings to younger and/or healthier individuals. 
In conclusion, our results are highly supportive of the beneficial role of the MeDiet 
for the prevention of CVD among subjects with abdominal obesity. Further studies 
are warranted, particularly to assess whether energy-restricted MeDiets can obtain an 
even greater benefit in abdominally obese subjects. In this line, we recently launched 
the PREDIMED-PLUS study (www.predimedplus.com), planning to recruit 6,000 
participants with abdominal obesity and will randomly allocate them to 2 diets: a) the 
control group will receive a traditional MeDiet without energy restriction (as the 
PREDIMED trial did); b) the intensive intervention group will receive an energy-
restricted MeDiet together with physical activity, goals for weight loss and behavioral 
therapy. Results are expected in 2020. 
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